MRC gains access to more deprioritized compounds

Seven companies committed to providing access to deprioritized compounds to the U.K.'s Medical Research Council for academic research projects. The council plans to publish a full list of the available compounds this year, and U.K. scientists will be able to apply for MRC funding to conduct their projects.The companies are AstraZeneca plc (LSE:AZN; NYSE:AZN); GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Eli Lilly and Co. (NYSE:LLY); the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ); Pfizer Inc. (NYSE:PFE); Takeda Pharmaceutical Co. Ltd. (Tokyo:4502); and UCB Group (Euronext:UCB). ...